Revolution Medicines, Inc. (RVMD)

Revolution Medicines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	699.18	163.15	110.23	105.35	16.87
Short-Term Investments	1,157	483.53	468.56	336.47	106.1
Cash & Cash Equivalents	1,856	646.68	578.79	441.83	122.97
Cash Growth	187.00%	11.73%	31.00%	259.29%	76.18%
Receivables	1.25	4.67	5.93	6.39	8.74
Other Current Assets	22.04	8.83	5.05	5.9	2.27
Total Current Assets	1,879	660.19	589.77	454.12	133.98
Property, Plant & Equipment	100.01	73.74	71.24	36.34	7.15
Goodwill and Intangibles	72.35	73.42	74.48	75.55	76.62
Other Long-Term Assets	10.06	4.59	2.5	1.39	2.78
Total Long-Term Assets	182.42	151.75	148.22	113.28	86.55
Total Assets	2,062	811.93	737.99	567.4	220.53
Accounts Payable	61.79	21.31	14.06	12.61	11.4
Deferred Revenue	0	4.46	18.93	20.59	31.85
Current Debt	7.37	6.77	6.21	3.67	0
Other Current Liabilities	74.69	29.45	21.15	10.3	-0.2
Total Current Liabilities	143.85	61.98	60.35	47.18	43.05
Long-Term Debt	80.58	57.43	60.42	28.99	0
Other Long-Term Liabilities	11.09	7.33	14.65	16.56	24.94
Total Long-Term Liabilities	91.66	64.76	75.07	45.55	24.94
Total Liabilities	235.51	126.74	135.42	92.73	67.99
Total Debt	87.94	64.21	66.63	32.66	0
Debt Growth	36.97%	-3.64%	104.00%	-	-
Retained Earnings	-1,137.71	-701.34	-452.64	-265.55	-157.39
Comprehensive Income	0.54	-1.78	-0.38	0.12	0.07
Shareholders' Equity	1,826	685.19	602.57	474.68	-152.57
Net Cash / Debt	1,768	582.48	512.16	409.16	122.97
Net Cash / Debt Growth	203.54%	13.73%	25.17%	232.73%	76.18%
Net Cash Per Share	15.63	7.22	7.03	7.46	44.35
Working Capital	1,735	598.2	529.42	406.95	90.93
Book Value Per Share	16.14	8.50	8.28	8.65	-55.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).